Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

@article{Lacy2006MayoCC,
  title={Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.},
  author={Martha Q. Lacy and Angela Dispenzieri and Morie A Gertz and Philip R. Greipp and Kimberly L Gollbach and Suzanne R. Hayman and Shaji K Kumar and John A. Lust and S Vincent Rajkumar and Stephen Russell and Thomas E Witzig and Steven R. Zeldenrust and David Dingli and P Lief Bergsagel and Rafael Fonseca and Craig B. Reeder and Alexander Stewart and Vivek Roy and Robert J. Dalton and Alan B. Carr and Deepak Kademani and Eugene E Keller and Christopher F. Viozzi and Robert A Kyle},
  journal={Mayo Clinic proceedings},
  year={2006},
  volume={81 8},
  pages={1047-53}
}
Bisphosphonates are effective in the prevention and treatment of bone disease in multiple myeloma (MM). Osteonecrosis of the jaw is Increasingly recognized as a serious complication of long-term bisphosphonate therapy. Issues such as the choice of bisphosphonate and duration of therapy have become the subject of intense debate given patient safety concerns. We reviewed available data concerning the use of bisphosphonates in MM. Guidelines for the use of bisphosphonates in MM were developed by a… CONTINUE READING